Not evaluated by SAHPRA. Research & educational information only — nothing is for sale; not intended to diagnose, treat, cure or prevent any disease.
EnergyResearch vialcibinetideanti-inflammatorynerve repairneuropathyEPO-derived
ARA-290
Non-erythropoietic EPO fragment that targets the innate repair receptor on injured tissue
- Format
- Research vial
- Strength / pack
- 10mg vial
- Category
- Energy
Innate repair receptorBinds the EPOR/CD131 heterocomplex on injured tissue
Anti-inflammatoryTriggers a pro-repair signalling cascade without raising red cells
Neuropathy dataReduced small fiber neuropathy symptom score in a sarcoidosis pilot
Metabolic signalLowered HbA1c by ~0.2% versus placebo in a T2D trial
ARA-290 (cibinetide) is an 11-amino-acid peptide engineered from the helix B region of erythropoietin. Unlike EPO it has no effect on red blood cell production — it binds the innate repair receptor (a heterocomplex of EPOR and CD131) on injured tissue, which triggers an anti-inflammatory and pro-repair signalling cascade. It holds FDA Orphan Drug designation for sarcoidosis-associated neuropathic pain.
More in Energy
Related research
EnergyPeptide vial
Research peptide vial
SLUPP Surge
A SLU-PP-332 research peptide designed to mimic the metabolic and physiological benefits of exercise. For energy, endurance and recovery.
Read the research →
EnergyResearch vial
40mg vial
MOTS-c
Improves energy production, insulin sensitivity, and metabolic health.
Read the research →
EnergyResearch vial
1000mg vial
NAD+
Supports cellular repair, anti-aging, mental clarity, and energy levels.
Read the research →
Publisher
Elegant Slimming · Mokopane, Limpopo, South Africa
Research library · nothing on this site is for sale.
Regulatory
This compound has not been evaluated by the South African Health Products Regulatory Authority (SAHPRA).
For information purposes only — not intended to diagnose, treat, cure or prevent any disease.